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Enhanced sensitivity of flow cytometry for 
routine assessment of minimal residual disease
In a recent paper by Béné and Kaeda,1 technical
approaches for minimal residual disease (MRD) assess-
ment are extensively reviewed. PCR-based studies have
proved to be 1-log more sensitive than flow cytometry
(FC). For this reason, they are increasingly being preferred
for MRD analysis, especially at the end of therapy or post
hematopoietic stem cell transplantation.1,2 It would be
valuable to develop MRD flow cytometry assays with this
level of sensitivity that could be applied routinely. In the
present work, we analyzed MRD+ samples with a level of
infiltration below the limit of detection of routine FC,
which is accepted as 10-4 and comes from the standard
acquisition of 2-5×105 leukocytes.3-11 At least 10-fold more
leukocytes must be acquired to increase sensitivity by 1-
log; this large number of leukocytes can be acquired easi-
ly in digital cytometers by acquiring several individual
tubes stained with the same combination of monoclonal
antibodies, and putting them in a single file. Because the
time of acquisition for each individual tube is not
increased, no problems of cellular aggregation arise. 
Using this approach, we acquired 6 million leukocytes
from each sample using a FACSCanto flow cytometer
(Becton-Dickinson). The stability of fluorescent parame-
ters between tubes was verified (Online Supplementary
Figure S1). The study was performed with the event rate
used routinely in our laboratory, i.e. 2,000 events/sec. To
explore the possibility of decreasing acquisition time, we
analyzed the influence of increasing the event rate on the
percentage of electronic aborts (due mainly to coincidence
events), and compared MRD measurements in samples
acquired at different event rates (Online Supplementary
Table S1). We found that the acquisition event rate could
be increased reliably to at least 4,000 events/sec. Using
this event rate, the time of acquisition of 6 million leuko-
cytes is suitable for routine measurements. 
We assessed that this approach enhanced sensitivity by
1-log by comparing MRD analysis by FC with real-time
quantitative PCR for BCR-ABL1p190 transcripts in serial
dilutions of a Philadelphia chromosome-positive B-II acute
lymphoblastic leukemia sample (Table 1A). We then
selected multiple myeloma (MM) and B-cell chronic lym-
phocytic leukemia (BCLL) MRD+ samples with about
0.01% infiltration and diluted them 10-fold with normal
leukocytes. As shown in Table 1B, MRD was detected
accurately in all diluted samples (10-5 infiltration).
Observed values were as expected ±10% in all cases.
This increase in sensitivity did not compromise the
specificity of the technique. Ten million leukocytes from
the bone marrow of patients (n = 3) without hematologic
neoplasias and from the peripheral blood of healthy
donors (n = 3) were acquired and blindly tested for the
presence of events with a myelomatous or B-CLL pheno-
type, respectively. The results were unambiguously nega-
tive (Online Supplementary Figure S2). We also acquired 10
million normal leukocytes and searched for events with
phenotypic characteristics of other hematologic malignan-
cies, such as follicular lymphoma and hairy cell leukemia,
with negative results.
In addition to the total number of leukocytes analyzed,
the sensitivity of FC depends on the number of neoplastic
events that must be detected in order to obtain precise
measurements.
Based on the theory that rare events follow a Poisson
distribution, it is accepted that 50-100 events are needed
to reliably measure the frequency of a population.3,7,8,11,12
However, to our knowledge, no studies have really meas-
ured the influence of the number of detected tumoral cells
on MRD measurement precision. Accordingly, we deter-
mined the coefficient of variation (CV) of the percentage
of MRD in samples from patients with MM, B-CLL and T-
cell lymphoproliferative disorders (T-CLPD) obtained
haematologica | 2010; 95(4) 691
Letters to the Editor
Table 1. Accuracy of minimal residual disease assessment in sam-
ples with infiltration <10-4. 
Sample Sample diluted 
10-fold
Number of acquired leukocytes 0.5 6
(millions)
MM 1 MRD (%) 0.0127 0.00127
# Cluster events 94 54
MM 2 MRD (%) 0.017 0.0017
# Cluster events 87 100
MM 3 MRD (%) 0.012 0.00118
# Cluster events 82 87
MM 4 MRD (%) 0.02 0.0018
# Cluster events 107 99
B-CLL 1 MRD (%) 0.015 0.0014
# Cluster events 78 114
B-CLL 2 MRD (%) 0.024 0.0022
# Cluster events 124 181
B-CLL 3 MRD (%) 0.025 0.0024
# Cluster events 139 151
B-CLL 4 MRD (%) 0.022 0.0024
# Cluster events 122 157
Sample Sample serially
diluted 10-fold
% MRD by FC 1.5 0.16 0.016 0.001
% MRD by RQ-PCR 4.9 0.33 0.025 0.001
(A) Minimal residual disease (MRD) levels measured by flow cytometry (FC) or
BCRABL1p190 transcripts quantitation by real-time quantitative PCR (RQ-PCR) in seri-
al dilutions of a Philadelphia chromosome-positive B-II acute lymphoblastic
leukemia bone marrow sample. MRD results by FC are expressed as percentage of
total leukocytes. MRD results by RQ-PCR are expressed as BCR-ABL1p190 copy number
per 100 molecules of GUS. (B) MRD levels measured by FC in samples with 10-5 infil-
tration: MRD+ samples with about 0.01% infiltration from 4 patients with multiple
myeloma (MM) and from 4 with B-cell chronic lymphocytic leukemia (B-CLL) were
assessed. The percentage of MRD for each sample (“Sample”) represents the mean
of 5 independent measurements. In each measurement, 0.5 million leukocytes were
acquired. These MRD+ samples were diluted 10-fold with normal leukocytes in order
to obtain tumoral infiltrations in the range of 10-5 (“Sample diluted 10-fold”). The per-
centage of MRD in diluted samples was measured by acquiring 6 million leukocytes.
The number of malignant events detected in each measurement is shown.
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when detecting increasing numbers of events in the malig-
nant cluster. As shown in Table 2, the CVs of the B-CLL
and T-CLPD samples were very close to those predicted
by the Poisson distribution. Fifty to 60 events were
required to obtain a CV less than 15%. Strikingly, in MM
samples, the CVs were around 10% regardless of the size
of the cluster, even when as few as 20 malignant events
were detected (possibly because it is easier to identify
malignant cells from MM than from other hematologic
malignancies, since myelomatous plasma cells usually
occupy a space in which background events are scarce).
In summary, acquiring 6 million leukocytes is feasible
with a digital cytometer on a routine basis. Because detec-
tion of 50-60 malignant cells is required to get a CV less
than 15%, a sensitivity of 1×10-5 is achieved. Being able to
routinely apply MRD FC assays with high sensitivity
would be very valuable, especially in cases where molec-
ular techniques cannot be used.
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Table 2. Precision of minimal residual disease assessment accord-
ing to the number of events in the malignant cluster.
# Cluster MRD CV
events (%) (%)
MM
Case 1 19 0.0127 9
43 0.013 10
94 0.0127 10
Case 2 30 0.018 10
44 0.017 10
87 0.017 9
Case 3 25 0.012 10
38 0.011 10
82 0.012 10
Case 4 39 0.021 8
54 0.02 10
107 0.02 10
Case 5 22 0.0027 9
42 0.003 10
91 0.003 8
B-CLL
Case 1 26 0.016 20
36 0.014 19
78 0.015 11
Case 2 37 0.023 18
60 0.023 14
124 0.024 7
Case 3 37 0.022 13
55 0.023 9
139 0.025 10
Case 4 36 0.021 9
62 0.023 12
122 0.022 10
Case 5 31 0.049 3
55 0.051 7
130 0.05 9
T-CLPD
Case 1 30 0.04 12
50 0.038 12
272 0.04 4
Case 2 25 0.025 20
47 0.024 13
79 0.026 11
Case 3 48 0.031 12
86 0.032 8
186 0.032 8
Case 4 57 0.031 12
106 0.031 8
193 0.03 2
Minimal residual disease (MRD) was measured in samples from 5 patients with
multiple myeloma (MM), 5 patients with B-cell chronic lymphocytic leukemia (B-
CLL), and 4 patients with T-cell lymphoproliferative disorders (T-CLPD) by detecting
three different levels of malignant cells (approximately 20-30, 40-60, and 80-200).
Results are presented as the mean of 5 independent trials. The CV was calculated as
(standard-deviation/mean) x 100.
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